Prebiotic Chicory Inulin- Digestive & Immune Health*
A recent study published in Ophthalmology Retina evaluated the relative risk associated with initiating GLP-1 agonist pharmacotherapy with these drug options on developing sight-threatening DR in routine clinical practice for patients with type 2 diabetes at moderate cardiovascular risk, which was defined as an annualized 1% to 5% predicted risk of experiencing a major adverse cardiovascular event
It does, however, offer non-GLP-1 products, such as ondansetron for nausea, and anti-aging compounds, including NAD+ injections and sermorelin
Medications that act like GLP-1 receptor agonists, such as semaglutide, are designed to mimic the functions of GLP-1 in the body
After consistent use for a few weeks, you will notice the changes
The men were then randomized to 1 year of different maintenance strategies: placebo, exercise, liraglutide 3.0 mg, or liraglutide + exercise (this was the S-LITE trial)